Titre : Protéines d'assemblage monomériques de la clathrine

Protéines d'assemblage monomériques de la clathrine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines d'assemblage monomériques de la clathrine : Questions médicales les plus fréquentes", "headline": "Protéines d'assemblage monomériques de la clathrine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines d'assemblage monomériques de la clathrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-21", "dateModified": "2025-03-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines d'assemblage monomériques de la clathrine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines adaptatrices du transport vésiculaire", "url": "https://questionsmedicales.fr/mesh/D033942", "about": { "@type": "MedicalCondition", "name": "Protéines adaptatrices du transport vésiculaire", "code": { "@type": "MedicalCode", "code": "D033942", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.990.150" } } }, "about": { "@type": "MedicalCondition", "name": "Protéines d'assemblage monomériques de la clathrine", "alternateName": "Monomeric Clathrin Assembly Proteins", "code": { "@type": "MedicalCode", "code": "D034041", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Liping Wang", "url": "https://questionsmedicales.fr/author/Liping%20Wang", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Jeanne C Stachowiak", "url": "https://questionsmedicales.fr/author/Jeanne%20C%20Stachowiak", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, United States." } }, { "@type": "Person", "name": "Margaret E Johnson", "url": "https://questionsmedicales.fr/author/Margaret%20E%20Johnson", "affiliation": { "@type": "Organization", "name": "TC Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, United States of America." } }, { "@type": "Person", "name": "Min Wu", "url": "https://questionsmedicales.fr/author/Min%20Wu", "affiliation": { "@type": "Organization", "name": "Department of Cell Biology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520-8002, USA. Electronic address: wu.min@yale.edu." } }, { "@type": "Person", "name": "Chun Wan", "url": "https://questionsmedicales.fr/author/Chun%20Wan", "affiliation": { "@type": "Organization", "name": "Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.", "datePublished": "2023-07-27", "url": "https://questionsmedicales.fr/article/37498324", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00262-023-03501-8" } }, { "@type": "ScholarlyArticle", "name": "C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.", "datePublished": "2024-06-04", "url": "https://questionsmedicales.fr/article/38893521", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules29112646" } }, { "@type": "ScholarlyArticle", "name": "The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.", "datePublished": "2023-03-25", "url": "https://questionsmedicales.fr/article/36966236", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41416-023-02218-w" } }, { "@type": "ScholarlyArticle", "name": "Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36889184", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.molimm.2023.02.007" } }, { "@type": "ScholarlyArticle", "name": "Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.", "datePublished": "2023-02-27", "url": "https://questionsmedicales.fr/article/36848319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cncr.34683" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Protéines du transport vésiculaire", "item": "https://questionsmedicales.fr/mesh/D033921" }, { "@type": "ListItem", "position": 6, "name": "Protéines adaptatrices du transport vésiculaire", "item": "https://questionsmedicales.fr/mesh/D033942" }, { "@type": "ListItem", "position": 7, "name": "Protéines d'assemblage monomériques de la clathrine", "item": "https://questionsmedicales.fr/mesh/D034041" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines d'assemblage monomériques de la clathrine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines d'assemblage monomériques de la clathrine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines d'assemblage monomériques de la clathrine", "description": "Comment diagnostiquer une anomalie des protéines de clathrine ?\nQuels examens sont recommandés pour évaluer la clathrine ?\nY a-t-il des biomarqueurs associés aux protéines de clathrine ?\nQuels symptômes peuvent indiquer un problème de clathrine ?\nLes tests d'imagerie sont-ils utiles pour la clathrine ?", "url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines d'assemblage monomériques de la clathrine", "description": "Quels symptômes sont liés à une dysfonction de la clathrine ?\nLa fatigue est-elle un symptôme associé ?\nDes douleurs musculaires peuvent-elles survenir ?\nY a-t-il des symptômes neurologiques associés ?\nLes troubles de la vision sont-ils possibles ?", "url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines d'assemblage monomériques de la clathrine", "description": "Comment prévenir les troubles liés à la clathrine ?\nY a-t-il des tests de dépistage recommandés ?\nLes vaccinations peuvent-elles aider ?\nLe stress peut-il affecter la clathrine ?\nDes conseils de mode de vie sont-ils disponibles ?", "url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines d'assemblage monomériques de la clathrine", "description": "Quels traitements sont disponibles pour les troubles de clathrine ?\nDes médicaments spécifiques existent-ils ?\nLa thérapie génique est-elle une option ?\nLes suppléments nutritionnels peuvent-ils aider ?\nLa rééducation est-elle recommandée ?", "url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines d'assemblage monomériques de la clathrine", "description": "Quelles complications peuvent survenir avec des troubles de clathrine ?\nLes troubles cognitifs peuvent-ils s'aggraver ?\nY a-t-il un risque accru de maladies associées ?\nDes problèmes de développement peuvent-ils survenir ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines d'assemblage monomériques de la clathrine", "description": "Quels sont les facteurs de risque pour les troubles de clathrine ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie influence-t-il le risque ?\nLes infections peuvent-elles être un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des protéines de clathrine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses protéomiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour évaluer la clathrine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'immunoblot et la microscopie électronique sont souvent utilisés." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés aux protéines de clathrine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de biomarqueurs spécifiques largement reconnus." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème de clathrine ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques ou des anomalies métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les tests d'imagerie sont-ils utiles pour la clathrine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les tests d'imagerie ne sont pas spécifiques pour les protéines de clathrine." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysfonction de la clathrine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la motricité, des problèmes cognitifs et des troubles métaboliques." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme associé ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fatigue peut être un symptôme indirect d'une dysfonction cellulaire." } }, { "@type": "Question", "name": "Des douleurs musculaires peuvent-elles survenir ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs musculaires peuvent être liées à des anomalies métaboliques." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des convulsions ou des troubles de l'équilibre peuvent apparaître." } }, { "@type": "Question", "name": "Les troubles de la vision sont-ils possibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la vision peuvent survenir en raison de dysfonctionnements neuronaux." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés à la clathrine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir certains troubles." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de tests de dépistage spécifiques pour ces troubles." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations ne sont pas directement liées à la prévention des troubles de clathrine." } }, { "@type": "Question", "name": "Le stress peut-il affecter la clathrine ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut avoir un impact négatif sur la santé cellulaire en général." } }, { "@type": "Question", "name": "Des conseils de mode de vie sont-ils disponibles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conseils incluent l'exercice régulier et la gestion du stress." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les troubles de clathrine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont symptomatiques et peuvent inclure des thérapies physiques." } }, { "@type": "Question", "name": "Des médicaments spécifiques existent-ils ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de médicaments spécifiques ciblant directement les protéines de clathrine." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore largement disponible." } }, { "@type": "Question", "name": "Les suppléments nutritionnels peuvent-ils aider ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments peuvent aider à gérer les symptômes, mais pas à traiter la cause." } }, { "@type": "Question", "name": "La rééducation est-elle recommandée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation physique peut aider à améliorer la fonction motrice." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des troubles de clathrine ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et métaboliques peuvent se développer." } }, { "@type": "Question", "name": "Les troubles cognitifs peuvent-ils s'aggraver ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les troubles cognitifs peuvent s'aggraver avec le temps." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles de clathrine peuvent augmenter le risque de maladies métaboliques." } }, { "@type": "Question", "name": "Des problèmes de développement peuvent-ils survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des retards de développement peuvent être observés chez certains patients." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais pas toutes sont réversibles." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles de clathrine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques et environnementaux peuvent influencer le risque." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles peuvent se manifester plus tard dans la vie." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles être un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent potentiellement affecter la fonction cellulaire." } } ] } ] }

Sources (10000 au total)

Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.

Disruptions in lipid metabolism and amino acids have been increasingly linked to resistance to immunotherapy. However, the underlying mechanisms by which dysregulated serum lipid metabolism and amino ... To elucidate the potential associations between lipid metabolism, amino acids, and PD-1/PD-L1, we employed the powerful Mendelian randomization (MR) method, leveraging large-scale genome-wide associat... In the present MR study, we identified a noteworthy negative association between alanine and PD-1 expression, implicating a regulatory role for alanine metabolism in modulating the immune response to ... These findings provided new insights into the role of lipid metabolism as well as amino acids in regulating PD-1/PD-L1, suggesting that strategies targeting lipid and amino acid metabolisms may have t...

C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.

The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positivel...

The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.

Tumour-infiltrating lymphocytes (TILs) represent a robust biological prognostic biomarker in triple-negative breast cancer (TNBC); however, the contribution of different subsets of immune cells is unc... In total, 259 patients with Stage I-III TNBC were reviewed. The density of sTILs along with the presence of total (t), stromal (s), and intratumoral (i) CD8... All immune markers were positively correlated with each other (P < 0.05). In the multivariate analysis, sTILs (P = 0.046), tCD8... In addition to sTILs, inclusion of tCD8...

Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.

Activation of PD-1 by anchoring it to Antigen Receptor (AR) components or associated co-receptors represents an attractive approach to treat autoimmune conditions. In this study, we provide evidence t...

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.

The availability of agents targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has transformed treatment of advanced and/or metastatic non-small ce...

EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR IN ENDOMETRIAL CANCER PATIENTS WITH METABOLIC DISORDERS.

To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders.... Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were us... In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation thera... Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity....

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China.

Programmed death receptor 1 (PD-1) inhibition has shown durable response and mild adverse events (AEs) in adult malignancies. However, data on the clinical activity of PD-1 inhibition in pediatric pat... We conducted a real-world, multi-institutional, retrospective analysis of pediatric malignancies treated with PD-1 inhibitor-based regimens. The primary endpoints were objective response rate (ORR) an... A total of 93 and 109 patients were evaluated for efficacy and safety, respectively. For all efficacy-evaluable patients, PD-1 inhibitor monotherapy, combined chemotherapy, combined histone deacetylas... This largest retrospective analysis demonstrate that PD-1 inhibitor-based regimens are potentially effective and tolerable in pediatric malignancies. Our findings provide references for future clinica...

Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.

Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation t...